2026 Q3 -tulosraportti
Vain PDF
69 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,71%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 10.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·12 t sittenWhat is Chemm doing? There are three interesting indirect signals. 1. Competitors are aggressively marketing to HiRes customers The most prominent example is Nova Biomedical, which has created an entire campaign page: “Looking for a Cedex HiRes Replacement?” They even offer a trade-in program and position FAST CDV as the natural successor to HiRes. This tells us that competitors expect HiRes customers to be actively looking for a new solution. 2. Beckman has made specific comparisons against HiRes Beckman has published data directly comparing Vi-CELL BLU with Cedex HiRes. This is classic “migration marketing”. 3. Software vendors continue to support HiRes An interesting finding is that Benchling as late as June 2026 released a new configuration guide for their Cedex HiRes data connector. This does not mean that Benchling expects HiRes to live on. It probably just means that many customers still use HiRes, and therefore need integration until the migration is completed. The most interesting absence For me, it's almost more interesting what isn't found. I have not found: * Roche cases on migration. * Customer cases on migration. * Beckman cases where a named Roche customer says they are switching. * CHEMM cases where a former HiRes customer talks about XM30. So the answer is Chemm isn't doing much to get the HiRes customers. Why not?Large companies like Amgen, Fujifilm Diosynth and Lonza belong to the relevant HiRes user group. But there is still no public customer case that shows who they choose after the phase-out.
·9.7.I've been looking at metec for a long time, and am in the process of researching the stock, but find the price difficult to assess. Can anyone here give me a brief idea about future pricing in your eyes and market share etc.? Is it now I should jump on board or will we dip again...? Thanks in advance🙏🏽
I bought in today, after having been a bit back and forth for a while. I am long-term and have cautiously set my expectations for an annual return of approx 10-11% I mainly base this on the expected annual growth, strong management with a solid focus on the business's growth model (the dividend certainly doesn't hurt either, even if it's modest). Of course, the stock might fall further in the short term, but personally, I believe in growth in the long run.- ·8.7.Who wins going forward - Chemo or Beckman? First, what is actually the difference between the technology of these two companies? ChemoMetec uses two fluorescent dyes, AO and DAPI, which are pre-filled in a sealed cassette. AO stains all cells, DAPI stains only dead cells. The instrument measures both populations simultaneously and directly, without anyone needing to touch the dyes. Beckman Coulter uses trypan blue, the classic method since 1964, which is added manually via pipette. Trypan blue is a fully acceptable method and is used with good reason throughout the industry. But it is not as precise as ChemoMetec's solution, as manual steps introduce variation. For many customers, this doesn't mean much. But in large-scale production across countries, where companies run multiple instruments in parallel and need to document that results are comparable across sites, it starts to matter. As I understand it, ChemoMetec is best in class here with under 5% instrument-to-instrument variation versus Beckman's approximately 10%. The industry is also moving in this direction. There is a clear trend towards closed, automated, and contamination-free systems in cell therapy production, which structurally favors cassette technology over open tube-based methods. The addressable market is also changing significantly. CAR-T started with blood cancer, small patient groups, and low volumes. Now the industry is targeting solid tumors and autoimmune diseases, which are potentially a much much larger market. At that scale, instrument-to-instrument variation means something entirely different than before, and this is where ChemoMetec's precision advantage becomes a real differentiator. In May 2026, the FDA issued new guidance on chemistry, manufacturing, and controls, requiring validated analytical methods to demonstrate precision, accuracy, and reproducibility. As I understand it, an instrument with under 5% variability and a pre-validated fixed-volume measurement architecture will be easier to include in a regulatory application than an instrument with 10% variability via a manual aspiration process. All in all, structural forces in the industry are moving towards ChemoMetec's technology. This does not mean that Beckman will disappear; they have an enormous installed base and will defend it fiercely. But the new programs, the new markets, and the regulatory landscape point in CHEMM's direction, as I understand it.
·1.7.Hmm, if the customer base is to move to Beckmann Coultier or others, they should soon announce something: The collaboration specifically aims to develop validated bioprocess monitoring solutions, beginning with integrating ChemoMetec's XM30 cell counter with the Cedex Bio Analyzer platform- 1.7."Roches Cedex HiRes Analyzer for cell analysis will be discontinued and will only be available for ordering until mid 2026. However, Cedex HiRes reagents, consumables, spare parts, and application support will remain available until March 2029, ensuring continued support throughout this period"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q3 -tulosraportti
Vain PDF
69 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,71%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenWhat is Chemm doing? There are three interesting indirect signals. 1. Competitors are aggressively marketing to HiRes customers The most prominent example is Nova Biomedical, which has created an entire campaign page: “Looking for a Cedex HiRes Replacement?” They even offer a trade-in program and position FAST CDV as the natural successor to HiRes. This tells us that competitors expect HiRes customers to be actively looking for a new solution. 2. Beckman has made specific comparisons against HiRes Beckman has published data directly comparing Vi-CELL BLU with Cedex HiRes. This is classic “migration marketing”. 3. Software vendors continue to support HiRes An interesting finding is that Benchling as late as June 2026 released a new configuration guide for their Cedex HiRes data connector. This does not mean that Benchling expects HiRes to live on. It probably just means that many customers still use HiRes, and therefore need integration until the migration is completed. The most interesting absence For me, it's almost more interesting what isn't found. I have not found: * Roche cases on migration. * Customer cases on migration. * Beckman cases where a named Roche customer says they are switching. * CHEMM cases where a former HiRes customer talks about XM30. So the answer is Chemm isn't doing much to get the HiRes customers. Why not?Large companies like Amgen, Fujifilm Diosynth and Lonza belong to the relevant HiRes user group. But there is still no public customer case that shows who they choose after the phase-out.
- ·9.7.I've been looking at metec for a long time, and am in the process of researching the stock, but find the price difficult to assess. Can anyone here give me a brief idea about future pricing in your eyes and market share etc.? Is it now I should jump on board or will we dip again...? Thanks in advance🙏🏽I bought in today, after having been a bit back and forth for a while. I am long-term and have cautiously set my expectations for an annual return of approx 10-11% I mainly base this on the expected annual growth, strong management with a solid focus on the business's growth model (the dividend certainly doesn't hurt either, even if it's modest). Of course, the stock might fall further in the short term, but personally, I believe in growth in the long run.
- ·8.7.Who wins going forward - Chemo or Beckman? First, what is actually the difference between the technology of these two companies? ChemoMetec uses two fluorescent dyes, AO and DAPI, which are pre-filled in a sealed cassette. AO stains all cells, DAPI stains only dead cells. The instrument measures both populations simultaneously and directly, without anyone needing to touch the dyes. Beckman Coulter uses trypan blue, the classic method since 1964, which is added manually via pipette. Trypan blue is a fully acceptable method and is used with good reason throughout the industry. But it is not as precise as ChemoMetec's solution, as manual steps introduce variation. For many customers, this doesn't mean much. But in large-scale production across countries, where companies run multiple instruments in parallel and need to document that results are comparable across sites, it starts to matter. As I understand it, ChemoMetec is best in class here with under 5% instrument-to-instrument variation versus Beckman's approximately 10%. The industry is also moving in this direction. There is a clear trend towards closed, automated, and contamination-free systems in cell therapy production, which structurally favors cassette technology over open tube-based methods. The addressable market is also changing significantly. CAR-T started with blood cancer, small patient groups, and low volumes. Now the industry is targeting solid tumors and autoimmune diseases, which are potentially a much much larger market. At that scale, instrument-to-instrument variation means something entirely different than before, and this is where ChemoMetec's precision advantage becomes a real differentiator. In May 2026, the FDA issued new guidance on chemistry, manufacturing, and controls, requiring validated analytical methods to demonstrate precision, accuracy, and reproducibility. As I understand it, an instrument with under 5% variability and a pre-validated fixed-volume measurement architecture will be easier to include in a regulatory application than an instrument with 10% variability via a manual aspiration process. All in all, structural forces in the industry are moving towards ChemoMetec's technology. This does not mean that Beckman will disappear; they have an enormous installed base and will defend it fiercely. But the new programs, the new markets, and the regulatory landscape point in CHEMM's direction, as I understand it.
- ·1.7.Hmm, if the customer base is to move to Beckmann Coultier or others, they should soon announce something: The collaboration specifically aims to develop validated bioprocess monitoring solutions, beginning with integrating ChemoMetec's XM30 cell counter with the Cedex Bio Analyzer platform
- 1.7."Roches Cedex HiRes Analyzer for cell analysis will be discontinued and will only be available for ordering until mid 2026. However, Cedex HiRes reagents, consumables, spare parts, and application support will remain available until March 2029, ensuring continued support throughout this period"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 10.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
2026 Q3 -tulosraportti
Vain PDF
69 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 10.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
7,00 DKK/osake
Viimeisin osinko
1,71%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenWhat is Chemm doing? There are three interesting indirect signals. 1. Competitors are aggressively marketing to HiRes customers The most prominent example is Nova Biomedical, which has created an entire campaign page: “Looking for a Cedex HiRes Replacement?” They even offer a trade-in program and position FAST CDV as the natural successor to HiRes. This tells us that competitors expect HiRes customers to be actively looking for a new solution. 2. Beckman has made specific comparisons against HiRes Beckman has published data directly comparing Vi-CELL BLU with Cedex HiRes. This is classic “migration marketing”. 3. Software vendors continue to support HiRes An interesting finding is that Benchling as late as June 2026 released a new configuration guide for their Cedex HiRes data connector. This does not mean that Benchling expects HiRes to live on. It probably just means that many customers still use HiRes, and therefore need integration until the migration is completed. The most interesting absence For me, it's almost more interesting what isn't found. I have not found: * Roche cases on migration. * Customer cases on migration. * Beckman cases where a named Roche customer says they are switching. * CHEMM cases where a former HiRes customer talks about XM30. So the answer is Chemm isn't doing much to get the HiRes customers. Why not?Large companies like Amgen, Fujifilm Diosynth and Lonza belong to the relevant HiRes user group. But there is still no public customer case that shows who they choose after the phase-out.
- ·9.7.I've been looking at metec for a long time, and am in the process of researching the stock, but find the price difficult to assess. Can anyone here give me a brief idea about future pricing in your eyes and market share etc.? Is it now I should jump on board or will we dip again...? Thanks in advance🙏🏽I bought in today, after having been a bit back and forth for a while. I am long-term and have cautiously set my expectations for an annual return of approx 10-11% I mainly base this on the expected annual growth, strong management with a solid focus on the business's growth model (the dividend certainly doesn't hurt either, even if it's modest). Of course, the stock might fall further in the short term, but personally, I believe in growth in the long run.
- ·8.7.Who wins going forward - Chemo or Beckman? First, what is actually the difference between the technology of these two companies? ChemoMetec uses two fluorescent dyes, AO and DAPI, which are pre-filled in a sealed cassette. AO stains all cells, DAPI stains only dead cells. The instrument measures both populations simultaneously and directly, without anyone needing to touch the dyes. Beckman Coulter uses trypan blue, the classic method since 1964, which is added manually via pipette. Trypan blue is a fully acceptable method and is used with good reason throughout the industry. But it is not as precise as ChemoMetec's solution, as manual steps introduce variation. For many customers, this doesn't mean much. But in large-scale production across countries, where companies run multiple instruments in parallel and need to document that results are comparable across sites, it starts to matter. As I understand it, ChemoMetec is best in class here with under 5% instrument-to-instrument variation versus Beckman's approximately 10%. The industry is also moving in this direction. There is a clear trend towards closed, automated, and contamination-free systems in cell therapy production, which structurally favors cassette technology over open tube-based methods. The addressable market is also changing significantly. CAR-T started with blood cancer, small patient groups, and low volumes. Now the industry is targeting solid tumors and autoimmune diseases, which are potentially a much much larger market. At that scale, instrument-to-instrument variation means something entirely different than before, and this is where ChemoMetec's precision advantage becomes a real differentiator. In May 2026, the FDA issued new guidance on chemistry, manufacturing, and controls, requiring validated analytical methods to demonstrate precision, accuracy, and reproducibility. As I understand it, an instrument with under 5% variability and a pre-validated fixed-volume measurement architecture will be easier to include in a regulatory application than an instrument with 10% variability via a manual aspiration process. All in all, structural forces in the industry are moving towards ChemoMetec's technology. This does not mean that Beckman will disappear; they have an enormous installed base and will defend it fiercely. But the new programs, the new markets, and the regulatory landscape point in CHEMM's direction, as I understand it.
- ·1.7.Hmm, if the customer base is to move to Beckmann Coultier or others, they should soon announce something: The collaboration specifically aims to develop validated bioprocess monitoring solutions, beginning with integrating ChemoMetec's XM30 cell counter with the Cedex Bio Analyzer platform
- 1.7."Roches Cedex HiRes Analyzer for cell analysis will be discontinued and will only be available for ordering until mid 2026. However, Cedex HiRes reagents, consumables, spare parts, and application support will remain available until March 2029, ensuring continued support throughout this period"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt